2014
Quantitative assessment of miR34a as an independent prognostic marker in breast cancer
Agarwal S, Hanna J, Sherman ME, Figueroa J, Rimm DL. Quantitative assessment of miR34a as an independent prognostic marker in breast cancer. British Journal Of Cancer 2014, 112: 61-68. PMID: 25474246, PMCID: PMC4453614, DOI: 10.1038/bjc.2014.573.Peer-Reviewed Original ResearchConceptsDisease-specific survivalBreast cancer cohortPoor disease-specific survivalDisease-specific deathIndependent breast cancer cohortsBreast cancerCancer cohortPoor outcomeCohort 1Multivariate Cox proportional hazards analysisCox proportional hazards analysisNode-positive populationX-tile softwareNode-negative patientsProportional hazards analysisTumor suppressorBreast cancer patientsIndependent prognostic markerExpression of miR34aReceptor statusNode statusPreclinical observationsTumor sizeCancer patientsCohort 2
2012
Measurement of Aldehyde Dehydrogenase 1 Expression Defines a Group with Better Prognosis in Patients with Non-Small Cell Lung Cancer
Dimou A, Neumeister V, Agarwal S, Anagnostou V, Syrigos K, Rimm DL. Measurement of Aldehyde Dehydrogenase 1 Expression Defines a Group with Better Prognosis in Patients with Non-Small Cell Lung Cancer. American Journal Of Pathology 2012, 181: 1436-1442. PMID: 22877687, DOI: 10.1016/j.ajpath.2012.06.037.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAldehyde dehydrogenase 1Cell lung cancerALDH1 expressionBetter prognosisLung cancerBreast cancerYale cohortQuantitative immunofluorescenceAldehyde dehydrogenase 1 (ALDH1) expressionPatras University HospitalSquamous cell carcinomaCancer stem cellsClinicopathologic factorsPoor outcomePrognostic valueRetrospective studyShorter survivalCell carcinomaUniversity HospitalSurrogate biomarkerFavorable outcomeLarge cohortTissue microarrayPatientsQuantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer
Agarwal S, Gertler FB, Balsamo M, Condeelis JS, Camp RL, Xue X, Lin J, Rohan TE, Rimm DL. Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer. Breast Cancer Research 2012, 14: r124. PMID: 22971274, PMCID: PMC3962029, DOI: 10.1186/bcr3318.Peer-Reviewed Original ResearchConceptsBreast cancer cohortBreast cancerPoor outcomeTumor cellsCancer cohortPoor disease-specific survivalDisease-specific deathDisease-specific survivalBreast cancer patientsIndependent prognostic markerIndependent breast cancer cohortsNon-invasive tumor cellsInvasive tumor cellsReceptor statusNode statusTumor sizeCancer patientsPrognostic markerSignificant associationCohortCancerIsoform expressionPatientsMetastasisOutcomes
2010
PMCA2 regulates apoptosis during mammary gland involution and predicts outcome in breast cancer
VanHouten J, Sullivan C, Bazinet C, Ryoo T, Camp R, Rimm DL, Chung G, Wysolmerski J. PMCA2 regulates apoptosis during mammary gland involution and predicts outcome in breast cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2010, 107: 11405-11410. PMID: 20534448, PMCID: PMC2895115, DOI: 10.1073/pnas.0911186107.Peer-Reviewed Original ResearchConceptsPMCA2 expressionBreast cancerT47D breast cancer cellsIntracellular calcium levelsBreast cancer progressionBreast cancer cellsEpithelial cell apoptosisPoor outcomeIntracellular calciumCalcium levelsMammary gland involutionCancer progressionCell apoptosisCancer cellsMammary involutionApoptosisGland involutionCancerMammary epithelial cell apoptosisOutcomesPMCA2Triggers apoptosisApical surfaceExpressionOverexpressionMultiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows that Both High and Low Levels of HER2 Are Associated with Poor Outcome
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh IT, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C, Ingle JN, Rimm DL, Hayes DF. Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows that Both High and Low Levels of HER2 Are Associated with Poor Outcome. American Journal Of Pathology 2010, 176: 1639-1647. PMID: 20150438, PMCID: PMC2843456, DOI: 10.2353/ajpath.2010.090711.Peer-Reviewed Original ResearchConceptsDisease-free survivalEstrogen receptorContinuous variablesSouthwest Oncology GroupAQUA methodAC chemotherapyMenopausal statusNegative patientsOncology GroupNode statusSequential doxorubicinPoor outcomeTumor sizeProgesterone receptorPrognostic informationWorse outcomesTissue biomarkersTissue microarrayBiphasic effectP53 expressionPatientsHER2Low expressersDiagnostic approachMultiplexed assessment
2009
Multiplexed AQUA-based assessment of SWOG 9313 shows prognostic value of continuous ER, PR and HER2 assessment.
Rimm D, Barlow W, Harigopal M, Tedeschi G, Peggy P, Yeh I, Haskell C, Livingston R, Hortobagyi G, Hayes D. Multiplexed AQUA-based assessment of SWOG 9313 shows prognostic value of continuous ER, PR and HER2 assessment. Cancer Research 2009, 69: 704. DOI: 10.1158/0008-5472.sabcs-704.Peer-Reviewed Original ResearchDisease-free survivalEstrogen receptorHER2 expressionWorse disease-free survivalPoor disease-free survivalContinuous variablesLow HER2 expressionPoor prognostic markerBreast cancer casesBreast cancer therapyBi-phasic effectSame slideHazard ratioMenopausal statusNode statusSequential doxorubicinPoor outcomePrognostic valueTumor sizePrognostic informationWorse outcomesPrognostic markerBreast cancerCancer casesTissue microarray
2007
Quantitative Analysis of Breast Cancer Tissue Microarrays Shows High Cox-2 Expression Is Associated with Poor Outcome
Zerkowski MP, Camp RL, Burtness BA, Rimm DL, Chung GG. Quantitative Analysis of Breast Cancer Tissue Microarrays Shows High Cox-2 Expression Is Associated with Poor Outcome. Cancer Investigation 2007, 25: 19-26. PMID: 17364553, DOI: 10.1080/07357900601128825.Peer-Reviewed Original ResearchConceptsCOX-2 expressionCOX-2Tissue microarrayBreast cancerEstrogen receptorPrognostic factorsWorse survivalProgesterone receptorX-tileOptimal cutpointHigh COX-2 expressionBreast cancer tissue microarrayX-tile analysisSignificant prognostic factorsPrimary breast cancerCOX-2 inhibitorsCancer tissue microarrayHER2/neuClinicopathologic factorsNodal statusPoor outcomePoor prognosisTumor sizePredictive biomarkersClinical trials
2006
Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma
Bellovin DI, Simpson KJ, Danilov T, Maynard E, Rimm DL, Oettgen P, Mercurio AM. Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma. Oncogene 2006, 25: 6959-6967. PMID: 16715134, DOI: 10.1038/sj.onc.1209682.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCadherinsCell Line, TumorColonic NeoplasmsEnzyme ActivationEpithelial CellsHumansImmunohistochemistryImmunoprecipitationNeoplasm InvasivenessPrognosisPromoter Regions, GeneticProto-Oncogene Protein c-ets-1Reverse Transcriptase Polymerase Chain ReactionRho GTP-Binding ProteinsRhoA GTP-Binding ProteinRhoC GTP-Binding ProteinRNA, Small InterferingTranscription, GeneticConceptsColon carcinomaRhoC expressionPrognostic markerRhoC protein expressionE-cadherinET-1 binding sitesClinical outcomesPoor outcomeColon cancer cellsColorectal tumorsET-1Colon cancerUse of shRNAMesenchymal transitionExpression correlatesCarcinomaAberrant expressionHigh expressionProtein expressionCancer cellsMesenchymal characteristicsEMTSubsequent activationReciprocal regulationCell migrationQuantitative In situ Analysis of β-Catenin Expression in Breast Cancer Shows Decreased Expression Is Associated with Poor Outcome
Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative In situ Analysis of β-Catenin Expression in Breast Cancer Shows Decreased Expression Is Associated with Poor Outcome. Cancer Research 2006, 66: 5487-5494. PMID: 16707478, DOI: 10.1158/0008-5472.can-06-0100.Peer-Reviewed Original ResearchConceptsProgesterone receptorEstrogen receptorPrognostic valueBreast cancerKi-67X-tile softwareProportional hazards modelBreast cancer prognosisBreast cancer showBreast cancer tumorsΒ-catenin expressionYale Pathology archivesHazard ratioNode statusPoor outcomeTumor sizePrognostic markerWorse outcomesImmunohistochemical studyNuclear gradeCase cohortLow-level expressionPathology archivesTissue microarrayBeta-catenin expression
2005
Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer
Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulos MA. Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer. Clinical Cancer Research 2005, 11: 8637-8643. PMID: 16361548, DOI: 10.1158/1078-0432.ccr-05-1436.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorOvarian cancerOverall survivalPrognostic valuePlatinum-paclitaxel combination chemotherapyAdvanced stage ovarian cancerDisease-free survivalSignificant prognostic factorsAdverse prognostic indicatorEpithelial ovarian cancerTumor EGFR expressionEGFR expression statusImportant prognostic informationConflicting resultsEpidermal growth factor receptor expression levelsEGFR protein expressionReceptor expression levelsGrowth factor receptorSurgical debulkingCombination chemotherapyPrognostic factorsMultivariable analysisEntire cohortPoor outcomePrognostic indicatorβ1,6-Branched Oligosaccharides Are Increased in Lymph Node Metastases and Predict Poor Outcome in Breast Carcinoma
Handerson T, Camp R, Harigopal M, Rimm D, Pawelek J. β1,6-Branched Oligosaccharides Are Increased in Lymph Node Metastases and Predict Poor Outcome in Breast Carcinoma. Clinical Cancer Research 2005, 11: 2969-2973. PMID: 15837749, DOI: 10.1158/1078-0432.ccr-04-2211.Peer-Reviewed Original ResearchConceptsLymph node metastasisPrimary tumorNode metastasisPoor outcomeBreast carcinomaNode-positive primary tumorsPatient-matched primary tumorsNode-negative tumorsBreast carcinoma metastasisPatient ageNodal metastasisTumor sizeRisk factorsNuclear gradeCarcinoma metastasisTissue microarrayBlinded observersMyeloid cellsMetastasisMultivariate analysisTumor progressionTumorsSystemic migrationCancer cellsLectin histochemistry
2004
Macrophage Colony-Stimulating Factor-1 Receptor Expression Is Associated with Poor Outcome in Breast Cancer by Large Cohort Tissue Microarray Analysis
Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, Rimm DL. Macrophage Colony-Stimulating Factor-1 Receptor Expression Is Associated with Poor Outcome in Breast Cancer by Large Cohort Tissue Microarray Analysis. Clinical Cancer Research 2004, 10: 173-177. PMID: 14734466, DOI: 10.1158/1078-0432.ccr-0699-3.Peer-Reviewed Original ResearchConceptsNode-positive patientsNode-negative patientsNode-positive casesCSF-1R expressionBreast cancerNodal statusOverall survivalPoor outcomeIpsilateral breast cancer recurrenceInvasive breast cancerNonmetastatic breast cancerPredictors of survivalNode-negative casesLarger tumor sizeSmall cohort studiesBreast cancer recurrenceCSF-1RTissue microarray analysisMacrophage colony-stimulating factor 1 receptorFactor 1 receptorTransmembrane tyrosine kinase receptorTyrosine kinase receptorsCohort studyColony-stimulating factor 1 receptorNodal involvement
2003
Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival.
Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z, Rimm DL. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Research 2003, 63: 8103-7. PMID: 14678960.Peer-Reviewed Original ResearchConceptsATF2 expressionTranscription factor 2Melanoma specimensUseful prognostic markerEarly-stage melanomaWeak cytoplasmic stainingStrong nuclear stainingFactor 2Mean followCutaneous specimensLocalized diseaseOverall survivalIndependent predictorsPreclinical findingsClark levelClinicopathological dataPatient survivalPoor outcomePrognostic valueWorse outcomesPrognostic markerPoor survivalPreclinical modelsClinical significanceImmunohistochemical stainingQuantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome.
Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Research 2003, 63: 1445-8. PMID: 12670887.Peer-Reviewed Original ResearchConceptsHER2 expressionLow-level HER2 expressionHER2/neu expressionHER2-overexpressing tumorsDisease-related survivalTissue microarray cohortNormal breast epitheliumBreast cancer tissuesMicroarray cohortPoor outcomeNeu expressionWorse outcomesBreast cancerImmunohistochemical stainsBreast epitheliumNormal epitheliumCancer tissuesBreast tumorsTumorsNormal levelsExpression levelsHER2AQUA analysisDetectable levelsLow group
2002
Tissue microarray‐based analysis shows phospho‐β‐catenin expression in malignant melanoma is associated with poor outcome
Kielhorn E, Provost E, Olsen D, D'Aquila TG, Smith BL, Camp RL, Rimm DL. Tissue microarray‐based analysis shows phospho‐β‐catenin expression in malignant melanoma is associated with poor outcome. International Journal Of Cancer 2002, 103: 652-656. PMID: 12494474, DOI: 10.1002/ijc.10893.Peer-Reviewed Original ResearchConceptsMalignant melanomaTissue microarray-based studyTissue microarray-based analysisWorse overall survivalDepth of invasionImmuno-histochemical analysisPhospho-specific antibodiesPhospho-β-catenin expressionOverall survivalMetastatic lesionsPrimary lesionPoor outcomePrognostic markerMelanomaUnique subsetNuclear stainingAntibodiesCatenin antibodyMicroarray-based analysisLesionsOutcomesCatenin expressionSer33/37/Thr41Microarray-based studiesHuman tissues